A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Lymphoma
DRUG: Glofitamab|DRUG: Tocilizumab|DRUG: Obinutuzumab|DRUG: Gemcitabine|DRUG: Oxaliplatin
Incidence of Adverse Events (AEs), Up to 3 years|Complete response (CR) rate, Up to 3 years
Objective response rate (ORR), Up to 3 years|Duration of response (DOR), From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 3 years)|Duration of CR, From the first occurrence of a documented CR to disease progression or death from any cause, whichever occurs first (up to 3 years)|Progression-free survival (PFS), From enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 3 years)|Overall Survival (OS), From enrollment to date of death from any cause (up to 3 years)|Serum concentration of glofitamab, Up to 3 years|Incidence of anti-drug antibodies to glofitamab, Baseline up to 3 years
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).